Anastrozole and Rosuvastatin Interaction

Avoid
Mechanism-based 75% confidence

Anastrozole and Rosuvastatin have a potentially harmful interaction with 75% confidence. Both Anastrozole and Rosuvastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the heart, so monitoring these systems is recommended.

Compound Profiles

Anastrozole

Aromatase Inhibitor | Estrogen Management

Anastrozole competitively binds to the heme group of the aromatase enzyme (cytochrome P450 19A1), reversibly inhibiting its catalytic activity. Aromatase is responsible for the final step in estrogen biosynthesis, converting testosterone to estradiol and androstenedione to estrone in peripheral tissues including adipose, muscle, liver, and brain.

Half-life: ~40-50 hours Typical dose: 0.25-0.5mg EOD or E3D (estrogen management) pct, anabolic
aromatase androgenicaromatase inhibitorestrogenichepatotoxic
View full profile

Rosuvastatin

HMG-CoA Reductase Inhibitor | Statin for Lipid Management

Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for hepatic cholesterol synthesis. By blocking this enzyme, rosuvastatin reduces intracellular cholesterol in hepatocytes, which triggers upregulation of LDL receptor expression on the liver cell surface.

Half-life: ~19 hours Typical dose: 5-20 mg/day cardiovascular
hepatotoxiclipid disruptingteratogenic
View full profile

Combined Organ Load

Gonads
moderate
Heart
moderate
Liver
moderate
Pituitary
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Anastrozole, Rosuvastatin). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds disrupt lipids (Anastrozole, Rosuvastatin). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (Anastrozole, Rosuvastatin). Monitor accordingly.

Frequently Asked Questions

Can I take Anastrozole with Rosuvastatin?

Combining Anastrozole with Rosuvastatin is not recommended. Both Anastrozole and Rosuvastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Anastrozole and Rosuvastatin safe together?

This combination carries significant risk. Both Anastrozole and Rosuvastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Anastrozole and Rosuvastatin?

Both Anastrozole and Rosuvastatin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 75% confidence and is inferred from pharmacological mechanism analysis.

How should I time Anastrozole and Rosuvastatin?

Anastrozole has a half-life of ~40-50 hours and Rosuvastatin has a half-life of ~19 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Anastrozole vs Rosuvastatin

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.